VRM
PCSA icon

Vectors Research Management’s Processa Pharmaceuticals PCSA Stock Holding History

Vectors Research Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed -$11K – 380
2022
Q2 		$11K Buy
+8
New +$11K ﹤0.01% 355
2022
Q1 		– Sell
-8
Closed -$20K – 535
2021
Q4 		$20K Hold
8
– – ﹤0.01% 341
2021
Q3 		$34K Hold
8
– – 0.01% 266
2021
Q2 		$33K Buy
+8
New +$30.9K 0.01% 269

Other funds holding PCSA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vectors Research Management's PCSA Position: Q3 2022 in Review

Vectors Research Management sold out of Processa Pharmaceuticals (PCSA) in Q3 2022, closing a stake of 8 shares — an estimated $11K sold.

Vectors Research Management first reported a position in PCSA in Q2 2021 and held it in 4 quarters. The position peaked at $34K in Q3 2021. 18 funds tracked by Wall St. Rank hold PCSA as of Q3 2022.

  • Vectors Research Management reported no remaining Processa Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Vectors Research Management sold 8 Processa Pharmaceuticals shares in Q3 2022, an estimated $11K.
  • Vectors Research Management first reported a position in Processa Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Vectors Research Management's Processa Pharmaceuticals position peaked at $34K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.